Table 1.
Baseline characteristics of enrolled participants
| Baseline characteristic | Study 1 |
Study 2a |
|
|---|---|---|---|
| Niacinamide (N = 10)b | Niacinamide (N = 18) | Placebo (N = 18) | |
| Age, mean (SD), yr | 34.4 (11.3) | 40.1 (10.9) | 44.7 (9.1) |
| Male sex, n (%) | 8 (80) | 10 (56) | 6 (33) |
| Race, n (%) | |||
| Caucasian, non-Hispanic | 9 (90) | 18 (100) | 18 (100) |
| Hispanic | 1 (10) | 0 (0) | 0 (0) |
| Hypertension, n (%) | 9 (90) | 18 (100) | 14 (78) |
| ACEI/ARB, n (%) | 6 (60) | 16 (89) | 13 (72) |
| htTKV, mean (SD), ml/m | 729 (319) | 1210 (772) | 1021 (434) |
| Irazabal class, n (%) | |||
| 1A | 0 (0.0) | 0 (0) | 0 (0) |
| 1B | 1 (11) | 3 (17) | 1 (6) |
| 1C | 3 (33) | 5 (28) | 10 (56) |
| 1D | 4 (44) | 5 (28) | 6 (33) |
| 1E | 1 (11) | 5 (28) | 1 (6) |
| 2 | 0 (0) | 0 (0) | 0 (0) |
| eGFR, mean (SD), ml/min per 1.73 m2 | 102.1 (16.7) | 78.1 (18.6) | 68.1 (12.0) |
ACEI/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; eGFR, estimated glomerular filtration rate; htTKV, height-adjusted total kidney volume.
a
In study 2, continuous measures were compared between treatment groups using the 2-sample t test. htTKV violated the assumption of normality, so this measure was log-transformed for inferential comparison. For categorical measures, Pearson’s χ2 test was used when expected cell counts were at least 5 in at least 80% of the cells; otherwise, Fisher’s exact test was used. No significant difference between treatment groups was detected.
b
N = 9 for htTKV and Mayo class.